Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
241-260 of 2,251 trials

Colitis from Cancer Treatment: The iCaD Study

We are comparing a new treatment combining infliximab with corticosteroids for severe colitis caused by immune checkpoint inhibitors. This study aims to see if this combination is more effective than corticosteroids alone.

Immune Checkpoint Inhibitor Related Colitis≤3 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyOncology

Advanced Thyroid and Head and Neck Cancer: [18F]AlF-PSMA-11 PET Study

We are investigating how well [18F]AlF-PSMA-11 PET detects cancer lesions in patients with advanced thyroid and head and neck carcinoma. This study compares its effectiveness to other imaging methods.

Head and Neck Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineOncologyOtolaryngology

Head and Neck Cancer: VB10.16 and Pembrolizumab

We are studying the safety and effectiveness of a new treatment combining VB10.16 with pembrolizumab for patients with HPV16-positive head and neck cancer. This trial aims to find the best dose and evaluate how well this combination works against the cancer.

Head and Neck Squamous Cell Carcinoma1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Gastrointestinal Stromal Tumor: Ripretinib vs Sunitinib

We are comparing two treatments for advanced gastrointestinal stromal tumors in patients with specific genetic mutations who have been treated before. The goal is to find out which medication may help control the disease better and improve quality of life.

Advanced Gastrointestinal Stromal TumorConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOncology

Advanced Solid Tumors: ODM-212 Study

We are testing a new oral medication, ODM-212, in patients with advanced solid tumors to evaluate its safety and how well it may work. This study aims to find the best dose and understand its effects on tumor growth.

Neoplasms (Tumors)>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Multiple Myeloma: HUVR-CARTemis-1 T-Cell Therapy

We are studying a new T-cell therapy for patients with multiple myeloma who have relapsed after an allogeneic transplant. The trial aims to evaluate the safety and effectiveness of this treatment over time.

Multiple Myeloma Progression>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Gastrointestinal Stromal Tumors: Imatinib and Atezolizumab Study

We are investigating whether combining imatinib with atezolizumab helps patients with advanced GIST who have not responded to other treatments. The study aims to assess survival rates and quality of life improvements.

Unresectable Gastrointestinal Stromal Tumor (GIST)Metastatic Gastrointestinal Stromal TumorLocally Advanced Gastrointestinal Stromal Tumor (GIST)>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Cystic Fibrosis: Vanzacaftor/Tezacaftor/Deutivacaftor Therapy

We are studying a new combination therapy for cystic fibrosis in individuals aged one year and older. The trial aims to evaluate its long-term safety and effectiveness.

Cystic Fibrosis>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicinePulmonology

Hodgkin Lymphoma: Tislelizumab Treatment Study

We are evaluating the safety and effectiveness of tislelizumab for patients with untreated Hodgkin lymphoma who cannot undergo standard chemotherapy. This study aims to see how well this treatment works and how it is tolerated.

Classical Hodgkin LymphomaEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Follicular Lymphoma: Odronextamab vs. Rituximab

We are studying whether odronextamab combined with lenalidomide is safer and more effective than rituximab combined with lenalidomide for adults with relapsed or refractory follicular lymphoma and marginal zone lymphoma.

Marginal Zone LymphomaFollicular Lymphoma6-12 monthsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Kidney Cancer: Savolitinib Plus Durvalumab Study

We are exploring whether a new combination treatment can help patients with advanced papillary renal cell carcinoma live longer and feel better compared to standard therapies.

Clear Cell Papillary Renal Cell CarcinomaConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteOncology

Limb Girdle Muscular Dystrophy 2E/R4: SRP-9003 Gene Therapy

We are studying a new gene therapy to see if it improves muscle function in people with Limb Girdle Muscular Dystrophy 2E/R4. The trial will evaluate its safety and effectiveness over time.

Limb-girdle Muscular Dystrophy Type 2E/R4>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Fabry Disease: PRX-102 for Children and Teens

We are studying the safety and effects of the drug PRX-102 in children and adolescents with Fabry disease. This research aims to understand how well it works and how it is processed in young patients.

Fabry's Disease1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyPediatrics

Recurrent Solid Tumors: IMA402 Treatment Study

We are testing a new treatment called IMA402 for patients with recurrent or hard-to-treat solid tumors. The study aims to evaluate its safety and how well it works, both alone and with another medication.

Solid TumorsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Melanoma: Lifileucel with Pembrolizumab

We are investigating whether a new treatment combining lifileucel with pembrolizumab is more effective than pembrolizumab alone for patients with untreated, advanced melanoma. The study aims to assess both effectiveness and safety.

MelanomaConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatologyOncology

Mucopolysaccharidosis Type II: JR-141 Treatment Study

We are investigating the long-term effects of JR-141 on symptoms of Hunter Syndrome. This study will help us understand its safety and effectiveness for patients with this condition.

Mucopolysaccharidosis IIHunter Syndrome>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNeurologyPediatrics

Sotorasib for Advanced Lung Cancer with KRAS G12C Mutation

We are studying whether sotorasib can help reduce tumor size in patients with advanced lung cancer who have other health conditions. The trial also looks at quality of life and safety during treatment.

KRAS G12C-Mutated Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineOncology

Vedolizumab for Kids with Ulcerative Colitis or Crohn’s Disease

We are studying a new injection form of Vedolizumab for children with moderate to severe ulcerative colitis or Crohn’s disease. The goal is to learn about its safety and how it works in the body after initial treatment.

Crohn's DiseaseUlcerative Colitis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Prostate Cancer: Long-Term Safety of Lutetium (177Lu) Treatment

We are investigating the long-term safety of lutetium (177Lu) vipivotide tetraxetan in adults with prostate cancer. This study aims to identify potential risks and serious side effects over time.

Prostate Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

PDA Treatment in Premature Infants: Acetaminophen and Ibuprofen Study

We are studying whether combining acetaminophen with ibuprofen helps extremely premature infants with a heart condition. The goal is to see if this combination reduces serious complications compared to ibuprofen alone.

Patent Ductus Arteriosus≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesCardiologyPediatrics